Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Sep 11th, 4:55 AM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 29.20 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
Download Workshop Manuals, the premier online destination for professional automotive repair documentation since 2005, today announced a major expansion of its digital workshop manual library, adding comprehensive coverage for the latest 2024-2025 model year vehicles across all major automotive segments.
Via Get News · September 10, 2025
The MeatStick V Wireless Smart Meat Thermometer has been honored with the Red Dot Award: Product Design 2025 in the Kitchen Appliances category, one of the world’s most respected design competitions.
Via Get News · September 10, 2025
HeartBeam Inc. (NASDAQ: BEAT) Advances Power of ECG with High-Fidelity At-Home Heart-Monitoring System
For decades, the traditional 12-lead electrocardiogram (“ECG”) has been the gold standard in cardiac diagnostics, including arrhythmia assessment, offering a comprehensive assessment of the heart’s electrical activity. However, traditional 12-lead ECG systems often come with limitations such as cumbersome setups and restricted accessibility. HeartBeam (NASDAQ: BEAT) is addressing these challenges by developing the HeartBeam System, the first cable-free, high-fidelity ECG system that captures the heart’s electrical signals from three distinct directions and synthesizes the signals into a 12-lead ECG, enabling comprehensive arrhythmia assessment outside clinical settings. This innovative approach aims to revolutionize cardiac care by providing patients with the ability to monitor their heart health conveniently and accurately.
Via Investor Brand Network · September 10, 2025
BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast
Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary RADR(R) AI platform, is featured in the latest episode of IBN’s BioMedWire Podcast. President, CEO and Director Panna Sharma discusses the company’s mission to accelerate cancer drug development using AI, outlines progress across three ongoing clinical trials and shares his outlook on the future of precision neuro-oncology.
Via Investor Brand Network · September 10, 2025
Qualcomm Sparks Retail Interest As Snapdragon Ride Pilot System Debuts In BMW iX3qualcom
Via Stocktwits · September 5, 2025
American households are bracing for a significant financial hit as a wave of tariff-induced inflation sweeps across critical consumer goods and services. From the family car to essential baby products, and even the cost of staying healthy, prices are already on an upward trajectory or are poised for substantial hikes.
Via MarketMinute · September 10, 2025
Nutriband Inc. (NASDAQ: NTRB): When Market Confidence Validates Scientific Innovation
The pharmaceutical sector is defined by a critical balance between innovation and validation. Breakthroughs can take years of research, but they only achieve true market credibility when investors, partners, or acquirers signal confidence in commercial potential. For companies tackling complex problems like opioid abuse, that validation becomes especially important.
Via Investor Brand Network · September 10, 2025
Tesla may still dominate the autonomous headlines, but Qualcomm’s partnership with BMW make it an interesting alternative for investors to consider.
Via MarketBeat · September 9, 2025
BioMedNewsBreaks — Gyre Therapeutics (NASDAQ: GYRE) Advances Toward China Approval and Expands Clinical Pipeline With Hydronidone
Gyre Therapeutics (NASDAQ: GYRE) has made strong progress through the first three quarters of FY2025, according to a report by Noble Capital Markets Senior Vice President and Equity Research Analyst Robert LeBoyer. The company posted continued sales growth from two recently launched products, submitted an application for Hydronidone approval in China, and initiated a U.S. Phase 2 trial for the drug. Gyre also named Dr. Han Ying, a board member since January 2025, as CEO. Phase 3 data for Hydronidone in chronic hepatitis B-associated fibrosis met its primary endpoint of fibrosis regression, supporting an NMPA filing in 3Q25. With Breakthrough Therapy Designation, approval is anticipated in 2H26, followed by commercial launch in FY2027.
Via Investor Brand Network · September 9, 2025
Soligenix Inc. (NASDAQ: SNGX) Showcases Expanding Rare Disease, Public Health Pipeline in Latest Corporate Presentation
Soligenix (NASDAQ: SNGX) has taken a bold step forward with its latest corporate presentation, offering investors and the broader biotech community a deeper look into the company’s evolving strategy and pipeline ( https://ibn.fm/YGu4N ). The presentation underscores Soligenix’s dual focus: pioneering therapies for rare diseases that lack adequate treatment options while simultaneously developing critical vaccines and countermeasures for emerging infectious threats and bioterrorism risks. This combination sets the company apart as both a champion for underserved patient populations and a strategic partner in global public health preparedness.
Via Investor Brand Network · September 9, 2025
Senior NIH Officials Allege Retaliation as Motive for Their Ouster
Two former officials at the NIH have filed whistleblower complaints in which they allege that their removal from office was a result of their resistance to giving politics priority over science and their efforts to defend vaccines and research grants. They filed their complaints last week.
Via Investor Brand Network · September 9, 2025
Nutriband Inc. (NASDAQ: NTRB) CEO Showcases AVERSA(TM) Abuse Deterrent Transdermal Technology at Emerging Growth Conference
The opioid crisis continues to highlight the urgent need for safer, more secure drug delivery methods, and Nutriband (NASDAQ: NTRB) is positioning itself as a company with a solution. At the August 2025 Emerging Growth Conference, Nutriband founder and president Serguei Melnik detailed the company’s lead product, AVERSA(TM), an abuse-deterrent transdermal technology that integrates aversive agents to prevent misuse, abuse and accidental exposure of drugs with high abuse potential, particularly opioids ( ibn.fm/1qrav ). With AVERSA(TM), Nutriband is aiming to transform traditional transdermal patches into safer tools for patients who require powerful pain relief, while simultaneously reducing the risks that have fueled a national epidemic.
Via Investor Brand Network · September 8, 2025
Analyst Ivan Feinseth attributes the revision to the company’s accelerating momentum in artificial intelligence, cloud computing, and its digital video platform, YouTube.
Via Stocktwits · September 5, 2025
Indian Tax Panel Recommends Additional Levies on Luxury EVs
Luxury electric cars in India may soon become more expensive for consumers if an Indian tax panel’s recommendation for additional levies on luxury EVs goes through. According to a government document, the tax panel is proposing higher consumer levies for electric cars that cost more than $46,000, a move designed to boost consumption of locally produced goods at the expense of foreign companies like Tesla, BYD, BMW, and Mercedes-Benz.
Via Investor Brand Network · September 5, 2025
NCI Halts Funding for Consortium Conducting Trials on Childhood Brain Cancers
The NCI, or National Cancer Institute, a federal body, has revealed that it will no longer fund a program that has been running for 26 years focused on advancing clinical studies on children with brain cancers.
Via Investor Brand Network · September 5, 2025
Qualcomm and BMW introduce Snapdragon Ride, a new automated driving platform for safety and driver assistance. Global debut in BMW iX3.
Via Benzinga · September 5, 2025
Soligenix Inc. (NASDAQ: SNGX) Advances Rare Disease Treatment with FDA Orphan Designation
Soligenix (NASDAQ: SNGX) has taken a decisive step forward in the fight against rare diseases, announcing that the FDA has granted orphan drug designation to its investigational therapy dusquetide for the treatment of Behçet’s disease ( https://ibn.fm/0t1aK ). This key FDA designation underscores not only the strength of recent phase 2 results but also the company’s growing reputation as a late-stage biopharmaceutical innovator dedicated to tackling serious, underserved conditions.
Via Investor Brand Network · September 4, 2025
The global financial landscape is currently in a state of heightened apprehension, grappling with a complex confluence of escalating geopolitical risks. The specter of President Trump's proposed "reciprocal tariffs," coupled with China's swift retaliatory measures and the persistent instability arising from international conflicts in Ukraine and the Middle East, is
Via MarketMinute · September 4, 2025
BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Subsidiary Publishes Landmark Primer on Oncology Real-World Evidence
Fifty 1 Labs (OTC: FITY) through its subsidiary Fifty1 AI Labs, announced the publication of a landmark technical primer on transportability methods in oncology real-world evidence (RWE) in the Journal of Comparative Effectiveness Research . Co-authored by CTO Alind Gupta and CEO Paul Arora, the paper showcases how advanced statistical and AI-driven frameworks can bridge data gaps, accelerate health technology assessments, and improve global access to life-saving therapies. With the oncology RWE market projected to expand from $789 million in 2024 to $3.51 billion by 2035 at a CAGR of 14.7%, the publication underscores Fifty1 Labs’ leadership in advancing drug repurposing and treatment access, particularly in rare diseases and underserved regions.
Via Investor Brand Network · September 4, 2025
Research Uncovers Possible Way to Repair Myelin in MS Patients
According to new research published in the journal Cell, targeting the SOX6 protein could open a new way to repair myelin in individuals afflicted by multiple sclerosis. According to the researchers, this SOX6 protein regulates the maturation of cells referred to as oligodendrocytes which manufacture myelin.
Via Investor Brand Network · September 4, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures $5.3 Million from Warrant Exercises to Advance AVERSA Fentanyl NDA
Nutriband (NASDAQ: NTRB), a company developing abuse deterrent pharmaceutical products, announced the exercise of warrants at a strike price of $6.43, generating $5,306,000 in proceeds. The funds will support the remaining clinical development of AVERSA Fentanyl and submission of its New Drug Application (NDA) with the U.S. Food and Drug Administration. AVERSA Fentanyl, which could become the world’s first opioid patch with abuse deterrent properties, is estimated to reach peak annual U.S. sales of $80 million to $200 million, according to a 2022 Health Advances market analysis report.
Via Investor Brand Network · September 4, 2025
BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Secures Exclusive U.S. Patent for Computer-Aided Diagnosis with Breast CT
Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company commercializing imaging-based technologies for improved breast cancer screening, diagnosis, and treatment, announced the issuance of the only U.S. patent for computer-aided diagnosis (CADx) with breast CT, covered under the Company’s exclusive global license agreement with the Regents of the University of California. CADx is an AI software tool that analyzes medical images to estimate malignancy likelihood and support radiologists in interpreting scans. In breast imaging, CADx is being developed to address limitations of mammography, digital breast tomosynthesis, ultrasound, and MRI by detecting subtle abnormalities, improving diagnostic consistency, reducing read times, and streamlining workflows.
Via Investor Brand Network · September 3, 2025
BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at H.C. Wainwright Global Investment Conference
Clene (NASDAQ: CLNN) announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference and host one-on-one investor meetings.
Via Investor Brand Network · September 2, 2025
Piedmont, SC - September 1, 2025 - Palmetto Complete Auto Care, a trusted provider of auto repair in Piedmont, SC, is proud to announce the approaching launch of its first website. This milestone is an important step in the shop’s commitment to offering convenience, clear communication, and exceptional service.
Via Get News · September 1, 2025
The Exclusive Transfer, Bangkok’s leading provider of luxury airport transportation, is honored to announce that it has been awarded Tripadvisor’s “Most Trusted Airport Transfer Service” recognition. This award is a testament to the company’s dedication to offering travelers a seamless, safe, and reliable experience when arriving at or departing from Suvarnabhumi and Don Mueang airports.
Via AB Newswire · September 1, 2025